Evidence map›Paper›PMID 39707602›Full record

ArticleInternational journal of cancer2025

Exploration of histone protein γ-H2AX as a prognostic factor in soft tissue sarcomas and its association with biological behavior, immune cell environment and survival in leiomyosarcoma.

Adrian Georg Simon, Su Ir Lyu, Anne Maria Schultheis, David Stahl, Nora Wuerdemann, Sebastian Walter, Lena Hieggelke, Reinhard Buettner, Christiane Josephine Bruns, Peer Eysel and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Adrian Georg SimonInstitute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.ORCID 0000-0002-2709-863X
Su Ir LyuInstitute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Anne Maria SchultheisInstitute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
David StahlDepartment I of Internal Medicine/Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Nora WuerdemannDepartment I of Internal Medicine/Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.ORCID 0000-0002-1092-689X
Sebastian WalterDepartment for Orthopedics and Trauma Surgery, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Lena HieggelkeInstitute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Reinhard BuettnerInstitute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Christiane Josephine BrunsDepartment of General, Visceral and Cancer and Transplant Surgery, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Peer EyselDepartment for Orthopedics and Trauma Surgery, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Lars Mortimer SchiffmannDepartment of General, Visceral and Cancer and Transplant Surgery, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Karl KnipperDepartment of General, Visceral and Cancer and Transplant Surgery, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Peter MallmannDepartment of Obstetrics and Gynecology, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Alexander QuaasInstitute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Roland UllrichDepartment I of Internal Medicine/Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates the H2AX/γ-H2AX expression in soft tissue sarcomas (STS), its implications for biological behavior and immune environment, and its potential as a prognostic biomarker. RNA-Seq data from 237 STS were obtained from The Cancer Genome Atlas project. Patients were stratified by H2AX mRNA expression using a survival-associated cutoff. Differentially expressed genes and pathways as well as immune signatures between H2AX

Indexed as

Biomarkers, TumorHistonesLeiomyosarcomaSarcomaAdultAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorH2AX protein, humanHistonesbiomarkerH2AXleiomyosarcomasoft tissue sarcomauterine leiomyosarcoma

Identifiers

PMID39707602
PMCPMC11970547

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.